

TIE-2 receptor agonists - Pipeline Insight, 2022

<https://marketpublishers.com/r/TED42ACFF52AEN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: TED42ACFF52AEN

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "TIE-2 receptor agonists - Pipeline Insight, 2022" report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in TIE-2 receptor agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

TIE-2 receptor agonists Understanding

TIE-2 receptor agonists: Overview

The tie receptors form another family of receptor tyrosine kinases. They are important for the regulation of angiogenesis together with the ligands of the tie-2 receptor, the Angiopoietins. The tie tyrosine kinase receptors, like the VEGF receptors, form the only receptor families that are predominantly expressed on endothelial cells. Most studies have focused on Ang-1 and Ang-2 which bind the Tie2 receptor and have the best characterized roles in angiogenesis. The roles of Ang-1 and Ang-2 signaling are complex and context dependent. Ang-1 binds and directly activates the Tie2 receptor, and this can have pro-angiogenic roles, stimulating EC sprouting and vessel growth as well as being correlated with vessel density in a variety of tumors.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence TIE-2 receptor agonists R&D. The therapies under development are focused on novel approaches for TIE-2 receptor agonists.

TIE-2 receptor agonists Emerging Drugs Chapters

This segment of the TIE-2 receptor agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

TIE-2 receptor agonists Emerging Drugs

AV-001: Vasomune Therapeutics

AV-001, a synthetic Angiopoietin 1 mimetic, activates the Tie2 receptor which is highly expressed on the surface of endothelial cells located within the vasculature.. AV-001 is designed to interact with the Tie2 receptor on a binding domain distinct from the natural ligands Angiopoietin 1 and Angiopoietin 2. Activation of Tie2 broadly promotes barrier defense against vascular leak and counteracts vascular inflammation by decreasing the activity of multiple pro-inflammatory factors. AV-001 represents a novel multifactorial approach that acts at the cellular and tissue-level. This approach is in contrast to the traditional highly specific lock and key therapies aimed at killing the pathogen or individual targets within the inflammatory response pathway. There are no clinically available medications to treat vascular leak.

Razuprotafib: Aadi Biosciences

Razuprotafib binds to and inhibits vascular endothelial protein tyrosine phosphatase (VE-PTP), an important negative regulator of Tie2. Decreased Tie2 activity contributes to vascular instability in many diseases including diabetes and more recently has been shown to contribute to the development of increased IOP and glaucoma. Razuprotafib

activates the Tie2 receptor irrespective of extracellular levels of its binding ligands, angiopoietin-1 (agonist) or angiopoietin-2 (antagonist) and we believe that it may be the most efficient pharmacologic approach to maintain normal Tie2 activation. Aerpio is studying a topical ocular formulation of razuprotafib in open angle glaucoma and exploring the utility of subcutaneous razuprotafib for diabetic complications, including diabetic nephropathy. In addition, a subcutaneous formulation of razuprotafib is being explored for its therapeutic potential in treating or preventing ARDS associated with COVID-19.

Further product details are provided in the report.....

TIE-2 receptor agonists: Therapeutic Assessment

This segment of the report provides insights about the different TIE-2 receptor agonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on TIE-2 receptor agonists

There are approx. 4+ key companies which are developing the TIE-2 receptor agonists. The companies which have their TIE-2 receptor agonists drug candidates in the most advanced stage, i.e. Phase II include, Aadi Biosciences.

Phases

DelveInsight's report covers around 6+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

TIE-2 receptor agonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

TIE-2 receptor agonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TIE-2 receptor agonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TIE-2 receptor agonists drugs.

TIE-2 receptor agonists Report Insights

TIE-2 receptor agonists Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

TIE-2 receptor agonists Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing TIE-2 receptor agonists drugs?

How many TIE-2 receptor agonists drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TIE-2 receptor agonists?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TIE-2 receptor agonists therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for TIE-2 receptor agonists and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Aadi Biosciences

Vasomune Therapeutics

AsclepiX Therapeutics

Q BioMed

PharmAbcine

Mannin Research

Key Products

Razuprotafib

AV 001

Gersizangitide

MAN 19

PMC 403

MAN 11

ARP 1536

Contents

Introduction

Executive Summary

TIE-2 receptor agonists: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

TIE-2 receptor agonists – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Razuprotafib: Aadi Biosciences

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

AV 001: Vasomune Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis
PMC 403: PharmAbcine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
TIE-2 receptor agonists Key Companies
TIE-2 receptor agonists Key Products
TIE-2 receptor agonists- Unmet Needs
TIE-2 receptor agonists- Market Drivers and Barriers
TIE-2 receptor agonists- Future Perspectives and Conclusion
TIE-2 receptor agonists Analyst Views
TIE-2 receptor agonists Key Companies
Appendix

I would like to order

Product name: TIE-2 receptor agonists - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/TED42ACFF52AEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TED42ACFF52AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970